Mosaic Uniparental Disomies and Aneuploidies as Large Structural Variants of the Human Genome  by Rodríguez-Santiago, Benjamín et al.
REPORT
Mosaic Uniparental Disomies and Aneuploidies
as Large Structural Variants of the Human Genome
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Montse Garcia-Closas,4 Manolis Kogevinas,6,7,8,9 Olaya Villa,1,2 Amy Hutchinson,10 Julie Earl,3
Gae¨lle Marenne,3 Kevin Jacobs,10 Daniel Rico,3 Adonina Tardo´n,7,11 Alfredo Carrato,12 Gilles Thomas,10
Alfonso Valencia,3 Debra Silverman,4 Francisco X. Real,1,3,16 Stephen J. Chanock,4,10,16
and Luis A. Pe´rez-Jurado1,2,13,14,16,*
Mosaicism is deﬁned as the coexistence of cells with different genetic composition within an individual, caused by postzygotic somatic
mutation. Although somatic mosaicism for chromosomal abnormalities is a well-established cause of developmental and somatic disor-
ders and has also been detected in different tissues, its frequency and extent in the adult normal population are still unknown. We
provide here a genome-wide survey ofmosaic genomic variation obtained by analyzing Illumina 1M SNP array data from blood or buccal
DNA samples of 1991 adult individuals from the Spanish Bladder Cancer/EPICURO genome-wide association study. We found mosaic
abnormalities in autosomes in 1.7% of samples, including 23 segmental uniparental disomies, 8 complete trisomies, and 11 large (1.5–37
Mb) copy-number variants. Alterations were observed across the different autosomes with recurrent events in chromosomes 9 and 20.
No case-control differences were found in the frequency of events or the percentage of cells affected, thus indicating thatmost rearrange-
ments found are not central to the development of bladder cancer. However, ﬁve out of six events tested were detected in both blood and
bladder tissue from the same individual, indicating an early developmental origin. The high cellular frequency of the anomalies detected
and their presence in normal adult individuals suggest that this type of mosaicism is a widespread phenomenon in the human genome.
Somatic mosaicism should be considered in the expanding repertoire of inter- and intraindividual genetic variation, some of whichmay
cause somatic human diseases but also contribute to modifying inherited disorders and/or late-onset multifactorial traits.Genetic mosaicism results from a postzygotic mutation
during development that is propagated to only a subset
of adult cells. It can occur in either or both somatic and
germline cells, the latter with the potential of passage to
offspring.1 Among the somatic or germline mutations
described in genetic mosaicism are point changes and
small rearrangements, as well as structural and numerical
chromosome aberrations.1,2 The most common form of
mosaicism detected by karyotyping in pre- and perinatal
diagnosis involves chromosomal aneuploidy, found in
~50% of preimplantation embryos, 1% of chorionic villous
samples, 0.2%–0.3% of amniotic ﬂuids, and 0.1% of
newborns.3,4 In single differentiated neurons, the average
frequency of aneuploidy has been determined as 1.25%–
1.45% per chromosome (30%–35% overall), with perhaps
lower frequency in other cell types.5,6 Acquiredmonosomy
of the X chromosome is a common type of mosaicism
observed in normal individuals that is associated with
aging.7 For large chromosomal structural variants, such
as copy-number variations (CNVs), mosaicism has been
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uals8 as well as divergence between identical twins;8,9 the
estimated frequency of postzygotic CNV could approach
5%. Molecular karyotyping with microarrays has also
been used to detect mosaicism for chromosomal rearrange-
ments and predict mutational mechanisms in clinical
samples referred for routine diagnostic analysis.10–15
Although the frequency of uniparental disomy (UPD),
the occurrence of two copies of a particular chromosome
from the same parent, is unknown, it has been invoked
as an important mechanism in carcinogenesis.16
The consequences of mosaicism nominally depend on
the altered genetic architecture and speciﬁcally how it
affects developmental and cell-speciﬁc pathways. So far,
the majority of somatic mutations have been described
in relation to clinical samples with a known phenotype,
thus representing mosaic aberrations with strong effect,
even though the mosaicism may result in either a milder
or unusual disease phenotype.10–15,17,18 However, mosaic
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high-throughput methods of genome analysis applied to
DNA obtained from samples containing large numbers of
cells. Thus, the frequency and relevance of mosaicism are
likely underestimated.
We provide here a survey of mosaic UPDs and segmental
and complete aneuploidies of the human genome by
molecular karyotyping with SNP arrays in 1991 adult indi-
viduals included in the Spanish Bladder Cancer/EPICURO
study: 1034 patients and 957 hospital-based controls with
amean age of 63.7 years (range 20–82 years), 87% of whom
were male.19,20 Cases were patients newly diagnosed with
urothelial cell carcinoma of the bladder (MIM 109800).
Controls were age-, sex-, and hospital-matched inpatients
mainly recruited from the general surgery and traumatol-
ogy departments with diagnoses not associated with
bladder cancer risk factors. The study was approved by
the institutional ethics committees of each participating
hospital and the institutional review board of the National
Cancer Institute (NCI, USA). Written informed consent
was obtained from all individuals. DNA was extracted
from peripheral blood with the Puregene DNA Isolation
Kit (Gentra Systems) formost cases (n¼ 1107) and controls
(n ¼ 1032) included in the analysis. DNA from an addi-
tional 43 cases and 117 controls was extracted from
mouthwash samples with phenol/chloroform. Formalin-
ﬁxed parafﬁn-embedded tissue blocks of tumors obtained
at surgery were also available from several cases.
Native genomic DNA was screened and analyzed at the
NCI according to the sample handling process of the Core
Genotyping Facility prior to analysis with the HumanHap
1M BeadChip (Illumina, Inc.) via the Inﬁnium Assay
following manufacturer recommendations. Overall, 2.6%
of controls were performed in duplicate, with SNP calling
concordance greater than 99.94%. Good-quality data were
obtained from 1991 samples, 1034 patients and 957
controls. Following a set of standardquality-controlmetrics
that used a hidden Markov model-based method21 with
stringent ﬁltering criteria,22 we identiﬁed 26,198 presum-
ably nonmosaic CNVs (see Figure S1 and Table S1 available
online). Among the samples discarded by ﬁltering, we
observed a few with an unusually high number of putative
CNVs concentrated across a single chromosome (n ¼ 20).
Inspectionof the signal intensity logR ratio (LogR) and frac-
tion of the total signal that was due to a speciﬁc allele (B
allele frequency, BAF) value plots of the affected regions re-
vealed single large aberrations with abnormal average BAF
value for heterozygous SNPs (not centered at 0.5) and either
(1) normal average LogR value around 0, indicating prob-
able copy-number neutral change with allelic imbalance
suggestive of a segmental UPD in mosaicism, or (2) altered
LogR values not reaching the chosen threshold for hetero-
zygous deletions or duplications (LogR > 0.2), suggesting
mosaic CNVs (Figure 1). We validated the predicted mosaic
rearrangements by multiplex ligation-dependent probe
ampliﬁcation (MLPA) and microsatellite analysis (see Table
S5 for sequence details) on the same source of DNA used for
the SNP array in all samples studied. We then performed130 The American Journal of Human Genetics 87, 129–138, July 9, 20a speciﬁc analysis to capture all BAF anomalies that might
correspond to large mosaic rearrangements in the entire
sample set in an unbiased manner (Figure S2). We used R
software (version 2.8.1) and the zoo package by basically as-
sessing B deviation values> 0.05 with LogR< 0.2. By using
a sliding-windows system (250 SNPs), we analyzed the
genome hybridization output of each sample with the es-
tablished cutoff ﬁxed parameters (R75 SNPs with desig-
nated B deviation and LogR values) to identify trend
changes along the chromosome analyzed (Figure S2). The
analysis parameters were ﬁrst set up with the 20 samples
known to harbor mosaic abnormalities already conﬁrmed
by other techniques, and the tool was then applied to the
whole data set. The performance of the method was tested
by the reanalysis of sampleswith previously deﬁnedmosaic
rearrangements, obtaining a 95% detection rate without
false positives in the remaining chromosomal regions.
We detected 23 potential UPD regions in 13 different
chromosomes from 20 individuals (13 patients and 7
controls). All UPDs involved segmental and terminal chro-
mosome fragments ranging in size from 6 Mb on chromo-
some 2p to ~96 Mb on 13q. Large CNVs with mosaicism
were identiﬁed in 11 samples (5 cases and 6 controls),
ranging in size from1.1 to 37.7Mb.Only onewas a duplica-
tion-typemosaic CNV, 26.3Mb in size, interstitial but adja-
cent to a terminal region of mosaic UPD on 1p. Eight entire
chromosome gains suggestive of mosaic trisomies (or other
polysomies) affecting six autosomes were identiﬁed in 7
samples (3 cases and 4 controls). Six individuals (4 cases
and 2 controls) showed more than one large mosaic rear-
rangement. Some rearrangementswere complex,with adja-
cent regions showing different degrees of mosaicism or
combination of CNV and UPD (Table 1; Table S2; Figure 2).
In order to estimate the proportion of cells with mosai-
cism in every case, we used BAF values from central popu-
lations of data points according to Illumina technical
notes. A sample with central populations of data points
at 0.55 and 0.45 BAF values for heterozygous SNPs was
considered to have 55% of chromosomes with a speciﬁc
allele and 45% of chromosomes with the other allele
(best estimates). We then used the B deviation (Bdev, devi-
ation from the expected BAF value of 0.5 for heterozygous
SNPs) to calculate the proportion of cells with the rear-
rangement depending on the type of mosaic rearrange-
ment: loss (deletion/monosomy; genotypes A/ and A/B),
gain (duplication/trisomy; genotypes AA/B and A/B), or
copy-number neutral change (UPD; genotypes A/A and
A/B). The simpliﬁed formulae used were as follows:
L ðproportion of cells with a lossÞ ¼ 2Bdev=ð0:5 þ BdevÞ
G ðproportion of cells with a gainÞ ¼ 2Bdev=ð0:5 BdevÞ
U ðproportion of cells with copy-
number neutral change; UPDÞ ¼ 2Bdev
In order to avoid false positive results due to experi-
mental data of poor quality, we discarded samples with
an average standard deviation of the BAF value above10
Figure 1. Examples of Different Types of Mosaic Rearrangements, Including Complex Rearrangements
The plots show the signal intensity log R ratio (LogR) (black dots, scale on the left side) and B allele frequency (BAF) (red dots, scale on the
right side) values along the entire chromosome carrying the rearrangements in selected samples. The length of the aberration is desig-
nated by the dashed blue lines; the type of rearrangement is annotated below.
(A) Mosaic uniparental disomy (UPD) in distal 1p characterized by unchanged LogR and abnormal heterozygous BAF in the indicated
interval; the interstitial mosaic duplication of the adjacent fragment shows elevated LogR (lower than the 0.2 cutoff for heterozygous
duplication calling) and abnormal heterozygous BAF.
(B) Large mosaic deletion in chromosome arm 9q showing decreased LogR and abnormal heterozygous BAF without complete loss of
heterozygosity.
(C) Mosaic trisomy 12 with a pattern similar to that of duplications along the entire chromosome.
(D) Mosaic UPD with different degrees of mosaicism for two adjacent regions of chromosome arm 7q.
(E) Large mosaic deletion in chromosome arm 20q (decreased LogR > 0.2 and abnormal heterozygous BAF). The complete loss of
heterozygosity of a genomic region overlapping with the mosaic deletion suggests the presence of complete UPD or homozygosity re-
sulting from identity by descent (IBD).
(F) Mosaic trisomy for the entire chromosome 9 (increased LogR). The different B deviation value between 9p and 9q with identical LogR
ratios in this sample also suggests the presence of UPD for 9p in addition to the trisomy.0.05. Given that the B deviation cutoff chosen for mosaic
rearrangement calling was then >0.05, our method can
be estimated to detect mosaicism only when the propor-
tion of affected cells is above 10%, 18%, or 23% for UPD,
deletions, and duplications and/or trisomies, respectively.
In theory, for samples yielding high-quality data (i.e.,
with standard deviation of BAF < 0.025), it would be
possible to detect much lower levels of mosaicism with
SNP arrays (about half of the above ﬁgures). The percentage
of cells carrying each rearrangement ranged from 17% to
82% in UPDs, 39% to 89% in deletions, 74% in the only
mosaic duplication, and 62% to 98% in trisomies (Table
1). The high proportion of affected cells in most detected
rearrangements suggests either the arousal of mutations
early in development or a positive selection for the rear-The Aranged cells. Furthermore, a signiﬁcant proportion of
mosaic rearrangements might remain undetected, mainly
those present in a lower proportion of cells, smaller than
1 Mb in size, or involving copy-number gains. Formal
testing for case-control differences in the frequency of rear-
rangements, divided by broad category of event or
percentage of cells affected, was clearly null in all cases,
thus suggesting that most rearrangements found are prob-
ably not central to the development of bladder cancer
(Table S3).
We validated by MLPA andmicrosatellite analysis on the
same source of DNA all 42 predicted mosaic rearrange-
ments (Table 1; Figure S3; see also Table S5 for sequence
details). We further analyzed tumor DNA and tumor tissue
sections from four cases of bladder cancer in which we hadmerican Journal of Human Genetics 87, 129–138, July 9, 2010 131
Table 1. Summary of Mosaic Rearrangements Detected
Sample Rearrangement Source Chr Start End Size (Mb) Validation % of Cells Bladder
Control 468a UPD blood 1p pter 31,505,375 31.5 Mi, MLPA 55%
duplication blood 1p 31,508,099 58,012,249 26.5 MLPA 74%
UPD blood 7q 69,769,236 qter 89 MLPA 48%
Case 197 deletion blood 5q 107,759,583 131,769,397 24 MLPA 39%
Control 771 deletion blood 9q 70,096,379 107,838,079 37.7 MLPA 39%
Case 1044 deletion blood 9q 82,074,397 104,355,425 22.2 MLPA 76%
Control 1014a deletion blood 11q 93,126,656 116,093,059 22.9 Mi 39%
trisomy/polysomy blood 12 pter qter 132 Mi, MLPA 69%c
Control 1017 deletion blood 16p pter 3,888,919 3.8 MLPA 58%
Case 1079 deletion blood 20q 30,488,149 31,745,200 1.2 MLPA 60%
Case 571 deletion blood 20q 30,491,175 48,812,965 18.3 Mi, MLPA 44%
Control 837 deletion blood 20q 30,824,044 48,140,963 17.3 Mi, MLPA 40%
Control 191b deletion blood 20q 30,489,196 48,819,540 18.3 Mi, MLPA 53%
Case 426a deletion blood 20q 33,993,320 53,443,077 19.4 Mi, MLPA 89% Mi, MLPA, FISH
trisomy/polysomy blood 9 pter qter 140 Mi, MLPA 95%c FISH
Control 577 trisomy/polysomy blood 8 pter qter 146 Mi, MLPA 62%c
Control 152 trisomy/polysomy blood 9 pter qter 140 Mi, MLPA 63%c
Case 1185a trisomy/polysomy blood 9 pter qter 140 Mi, MLPA 72%c Mi, MLPA, FISH
UPD blood 9p pter 38,987,691 38.9 Mi, MLPA d
trisomy/polysomy blood 22 pter qter 49.7 Mi, MLPA 74%c FISH negative
Case 511 trisomy/polysomy blood 15 pter qter 100 MLPA 60%c
Control 541 trisomy/polysomy blood 19 pter qter 63.8 Mi, MLPA 98%c
Control 776 UPD blood 2p pter 5,974,108 5.9 MLPA 28%
Control 196 UPD blood 2q 210,673,136 qter 32.3 Mi, MLPA 51%
Case 954 UPD blood 2q 218,476,667 qter 24.5 MLPA 22%
Case 155 UPD blood 3p pter 43,770,009 43.3 MLPA 18%
Case 1105e UPD blood 7q 62,401,114 96,812,073 34.4 MLPA 29%
UPD blood 7q 96,934,617 qter 61.9 MLPA 18%
Control 586 UPD blood 9p pter 39,102,964 39.1 MLPA 83%
Control 843 UPD blood 11q 65,547,103 qter 69.2 MLPA 22%
Case 125 UPD blood 12q 55,481,646 qter 82.3 MLPA 17%
Case 234 UPD blood 13q 17,956,717 qter 96.2 MLPA 18%
Case 962a UPD blood 13q 19,554,439 qter 94.5 Mi 28%
UPD blood 17p pter 18,649,825 18.6 Mi 39% Mi
Case 787 UPD blood 14q 23,303,146 qter 83 Mi 34%
Case 758 UPD blood 14q 74,454,224 qter 31.9 MLPA 18%
Case 1205 UPD buccal 16p pter 14,565,117 14.5 Mi, MLPA 25%
Case 815 UPD blood 17p pter 4,724,664 4.7 Mi, MLPA 34% Mi, MLPA, FISH
Case 369 UPD blood 17q 37,339,650 qter 41.4 MLPA 28%
Control 1007 UPD blood 17q 53,007,738 qter 25.8 Mi, MLPA 21%
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Table 1. Continued
Sample Rearrangement Source Chr Start End Size (Mb) Validation % of Cells Bladder
Control 670 UPD blood 19q 48,312,997 qter 15.7 MLPA 21%
Case 138 UPD blood 21q 31,600,986 qter 14.9 MLPA 20%
A total of 42 rearrangements were found in 34 individuals (19 cases and 15 controls). All observations (42 of 42) were confirmed on the original DNA used for SNP
arrays. The start and end point of each rearrangement correspond to the coordinates of the first SNP or probe located within the rearrangement, based on B allele
frequency (BAF) and signal intensity log R ratio (LogR) DNA segment values detected with described tools (see text and Figure S2). Additional studies on bladder
tumor DNA and tissue were performed in a subset of samples (column ‘‘Bladder’’). The following abbreviations are used: UPD, uniparental disomy; pter and qter,
p-terminal and q-terminal ends of chromosomes; Mi, microsatellite markers; MLPA, multiplex ligation probe-dependent amplification; FISH, fluorescence in situ
hybridization.
a Samples with more than one rearrangement.
b Complete loss of heterozygosity with identical LogR values in an overlapping region (Mb 27–44) in 20q, suggestive of complete UPD and/or identity by descent
and mosaic (distal) deletions (Figure 1).
c Mosaicism estimation assuming all the cells with the rearrangement are trisomic for the indicated chromosome. The proportion may differ from the estimation if
there are cells with other polysomies (tetrasomic or other) in the samples.
d Different BAF and identical LogR values between 9p and 9q, suggestive of 9p UPD in addition to whole chromosome 9 trisomy.
e Different BAF value between the two regions of 7q with similar average LogR, suggestive of different degrees of mosaicism for UPD.detected alterations in blood DNA (cases 962, 426, 815,
and 1185). Using microsatellite analysis, we conﬁrmed
the allelic imbalances in tumor DNA indicative of the
17p UPDs, 20q deletion, and chromosome 9 trisomies
(Figure 3); by contrast, the chromosome 22 gain was not
detected in the tumor cells. The mosaic rearrangements
were also conﬁrmed by ﬂuorescence in situ hybridizationFigure 2. Genomic Distribution of Mosaic Events Detected
The illustration summarizes the chromosomal location and
approximate size of all the mosaic events detected along the auto-
somal chromosomes: 23 UPDs (blue lines), 8 trisomies (red lines),
one duplication (pink line), and 10 deletions (green lines). No
alterations involving chromosomes 4, 6, 10, or 18 were found.
Chromosomes are drawn to scale (tick marks indicate 10 Mb).
Asterisks (*) indicate events found in a bladder cancer patient.
The A(FISH) with speciﬁc probes in tumor cells of three samples
(Figure 3). Therefore, mosaicism was present in two tissues
from the same individual with different embryonic origin,
suggesting that the 17p UPDs, 20q deletion, and trisomies
9 (5 out of 6 tested rearrangements) must have arisen early
in development. A previous report identiﬁedmosaic CNVs,
ranging in size from 82 to 176 kb, in a diverse range of
organs and tissues, some cell-type speciﬁc and some
present in all tissues.9 Therefore, mutational events and
chromosome instability leading to mosaicism can occur
early in embryonic development but also in late mitosis
affecting a single tissue.23–26
Although none of the mosaic UPD regions detected in
different individuals were identical in size and/or break-
points, shared genomic intervals occurred at 2q, 7q, 13q,
17p, and 17q. Interestingly, mosaic UPD including almost
the entire 13q armwas found in bloodDNA from two unre-
lated bladder cancer patients who also had deletion-type
heterozygous CNVs overlapping ~833 kb at 13q14
(Figure 4). This deletion maps in the vicinity of the RB1
locus commonly deleted in bladder tumors, encompasses
several candidate cancer genes (DLEU1, DLEU2, and
DLEU7), and could alter expression of two cancer-related
microRNAs (miR-15a and miR-16-1) located in an intron
ofDLEU2.27–29 The co-occurrence in twounrelated patients
withbladder cancer of two rare chromosomeabnormalities,
germline 13q14 deletion and mosaic UPD 13q, suggests
that these abnormalities could be mechanistically linked
and/or related to disease. Heterozygous deletions can repre-
sent susceptibility factors for mitotic instability leading to
UPD, as shown for some meiotic rearrangements.30 The
potential pathogenic involvement of these rearrangements
may depend on the proportion of UPD, susceptibility to
nullizygosity, or tissue-speciﬁc gene effects.
Whereas 10 of 11 mosaic CNVs were interstitial, all 23
segmental UPDs detected were terminal, likely resulting
from a postfertilization error during early mitotic divisions
mediated by single events of somatic homologous recom-
bination. The mechanisms of somatic reshufﬂing leading
to UPD are not well deﬁned, and some argue that hot spotsmerican Journal of Human Genetics 87, 129–138, July 9, 2010 133
Figure 3. Representative Mosaic Rearrangements Validated by Independent Methods
Validation was performed on the same source of DNA used for the SNP array (multiplex ligation-dependent probe ampliﬁcation [MLPA]
andmicrosatellites) as well as on DNA (microsatellites) and tumor tissue sections (ﬂuorescence in situ hybridization [FISH]) from bladder
tumor tissue. The plots at left show the LogR ratio (black dots) and BAF (red dots) values along an entire chromosome in selected samples
(bottom) compared to the wild-type pattern (WT, top).
(A) Segmental UPD of 17p terminal in case 815. MLPA (P060 panel) conﬁrmed the disomic state at the UPD loci with no gain or loss of
genetic material (1.0 relative peak height [RPH]), microsatellite analysis ratiﬁed the allelic imbalance both in blood and bladder tumor
DNA reﬂected by an aberrant ratio between allelic peaks with respect to the control sample, and FISH showed two signals corresponding
to disomy in all nuclei (tan arrowheads in panel at right).
(B) Full trisomy 9 with additional UPD of 9p. MLPA conﬁrmed a gain of genetic material at the trisomic locus (1.3 RPH), and microsa-
tellite analysis ratiﬁed the allelic imbalance without detecting third alleles in both blood and bladder tumor DNA (shown by upward and
downward arrows in middle panel). Right panel: FISH on bladder tumor tissue revealed a mosaic pattern of interphase cell nuclei with
two (disomic, tan arrowheads), three (trisomic, white arrowheads; ~30%), or four or more (tetrasomic or polysomic; ~10%) signals.
(C) Large (19.4Mb) deletion-type copy-number variation (CNV) on chromosome 20q.MLPA conﬁrmed a loss of geneticmaterial at three
loci within the interval, andmicrosatellite analysis ratiﬁed an allelic imbalance in both blood and bladder tumor DNA. Right panel: FISH
on bladder tumor tissue revealed a mosaic pattern of interphase cell nuclei with either one (monosomic, white arrowheads) or two
(disomic, tan arrowheads) signals. The percentage of cells carrying the rearrangement was higher in blood than in tumor cells in all three
cases, as revealed by the greater degree of allelic imbalance.can play a role.31,32 We deﬁned the breakpoint intervals for
all segmental rearrangements as the regions between two
informative SNP probes (within and outside the rearrange-
ment) and analyzed whether they shared any genomic
features, including their overlap with recombination hot
spots of the human genome,33 segmental duplications,
or structural variation.34,35 We calculated permutation
p values by randomizing the positions of breakpoints
across the genome 1000 times and measuring the number
of times that the breakpoints overlapped with different134 The American Journal of Human Genetics 87, 129–138, July 9, 20genomic features; p values were calculated as the number
of times that the observed value equaled or exceeded the
expected value in the randomized set, divided by the total
number of permutations plus one. Six UPD breakpoint
intervals localized to segmental duplications (28.5%, ~53
enrichment, p ¼ 0.003), six overlapped with meiotic
crossing-over hot spots (~4.33 enrichment, p ¼ 0.209),
and ten mapped within copy-number-variable regions
(~23 enrichment, p ¼ 0.035), suggesting that mitotic rear-
rangements are mediated by mechanisms similar to those10
Figure 4. Overlapping Rearrangements in Leukocyte DNA Samples from Two Patients with Bladder Cancer
The plots on the bottom show themosaic UPDs including almost the entire chromosome 13q found in bloodDNA of two bladder cancer
patients who also shared deletion-type heterozygous CNVs overlapping ~833 kb at 13q14 (chr13 coordinates: 49539177–50372054).
Analysis of the average LogR of the probes within the CNV yielded below-average LogR ratio for heterozygous deletion values in case
234 (left) and average values in case 962 (right); loss of heterozygosity was also found in case 234, whereas case 962 displayed values
compatible with heterozygosity in 1/3 of SNPs within the interval, indicating that the disomic chromosome was the one carrying
the CNV in case 234 whereas the other chromosome carried the CNV in case 962. The size of the deletions and overlapping fragment
is represented by green bars illustrating their relative location with respect to the chromosome 13 ideogram and showing related
genomic features: gene content (including distant RB1 gene), CNVs (Database of Genomic Variants, March 2010 version), and segmental
duplications.of meiotic recombination (Table S4). No signiﬁcant
enrichment of sequence motifs was identiﬁed in the 19
breakpoints of the large CNVs. However, we found ﬁve
overlapping deletion-type CNVs in chromosome 20q,
some of which shared breakpoints (Figure 5; Table S4).
Interestingly, similar deletions that may harbor tumor
suppressor genes have been recurrently reported in myelo-
dysplastic syndromes and in Philadelphia chromosome-
negative myeloproliferative disorders.36,37 These ﬁndings
further indicate the existence of hot spots for somatic
recombination in chromosome 20q.
In our survey, chromosome 9 had the highest rearrange-
ment rate (two large 9q deletions, two 9p UPDs, and three
complete trisomies), suggesting an increased somatic insta-
bility for this chromosome,but further studies areneeded to
evaluate this observation. It is plausible that chromosome 9
structural variants, such as the polymorphic pericentric
inversion present in ~0.85%of the population,may behave
as susceptibility factors for somatic instability.38The AAlthough large-scale mosaic events have been detected
before, they were primarily observed in subjects from
clinic-based studies, where screened individuals have high
prior likelihood for one or more genetic causes associated
with their condition. Our ﬁndings provide evidence for
a greater complexity of the human genome with respect to
structural events. Somatic mosaicism for large structural
autosomal chromosome abnormalities, including CNVs,
aneuploidies, and copy-number neutral changes due to
segmental UPD, appears to be present in blood or buccal
cells, both DNA sources with a spectrum of well-differenti-
ated cell types, of 1.7% of the adult population. The high
cellular frequency of most mosaic anomalies detected and
their presence in normal adult individuals suggest that this
type of mosaicism is a widespread phenomenon of the
human genome with possible phenotypic consequences,
thoughalmosthalf ofourobservedeventsoccurred inother-
wise healthy elderly controls. Somatic mosaicism should be
considered in the expanding repertoire of inter- andmerican Journal of Human Genetics 87, 129–138, July 9, 2010 135
Figure 5. Overlapping Mitotic Interstitial Deletions of Chromo-
some 20q in Five Unrelated Individuals
Aligned plots of LogR ratio (black) and BAF (red) values along the
entire chromosome 20 of the ﬁve individuals, showing the rear-
rangements and the similar breakpoints (joined by dashed vertical
red lines).
136 The American Journal of Human Genetics 87, 129–138, July 9, 20intraindividual genetic variation, some of which causes
somatic human diseases but also modiﬁes penetrance and/
or expressivity of inherited disorders and late-onset multi-
factorial traits. When affecting the germline, these abnor-
malities could also contribute to infertility, recurrentmiscar-
riages, or recurrent anomalies in offspring.39
It is highly possible that the mosaic occurrence of
genomic variants, especially UPD, may have been missed
previously with the standard analytical procedures applied
to CNV detection in published studies with SNP arrays.
Moreover, our quality-control metrics could also lead to
an underestimation of the events, even within our study.
It is also plausible that some of the CNVs registered in
the database of genomic variants might correspond to
mosaic rearrangements. Thus, optimization of the analysis
of data obtained with SNP arrays, as well as the develop-
ment of similar algorithms for the analysis of high-depth
coverage data obtained with next-generation sequencing,
is required to improve the accurate detection of these
events in human populations. Capturing and classifying
all relevant genomic variation features in cells from
different tissues, and at different developmental stages,
constitutional or acquired, should lead to a better under-
standing of the complex and evolving human genome
and its relation to both diseases and traits.Supplemental Data
Supplemental Data include three ﬁgures and ﬁve tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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